| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 23, 2006
Accepted on November 27, 2006
From the Institute of Pathophysiology (P.K., S.L., K.v.W.L., G.H., B.L.), University Hospital Essen, and the Med. Klinik IV (M.T., M.S., M.v.d.G.), Charite - Campus Benjamin Franklin, Berlin, Germany.
* To whom correspondence should be addressed. E-mail: levkau{at}uni-essen.de.
Objective--The sphingosine-1-phosphate (S1P) analogue FTY720 is a potent immunosuppressive agent currently in Phase III clinical trials for kidney transplantation. FTY720 traps lymphocytes in secondary lymphoid organs thereby preventing their migration to inflammatory sites. Previously, we have identified FTY720 as a potent activator of eNOS. As both inhibition of immune responses and stimulation of eNOS may attenuate atherosclerosis, we administered FTY720 to apolipoprotein E-/- mice fed a high-cholesterol diet.
Methods and Results--FTY720 dramatically reduced atherosclerotic lesion volume (62.5%), macrophage (41.8%), and collagen content (63.5%) after 20 weeks of high-cholesterol diet. In isolated aortic segments and cultured vascular smooth muscle cell, FTY720 potently inhibited thrombin-induced release of monocyte chemoattractant protein-1. This effect was mediated by the S1P3 sphingolipid receptor as FTY720 had no effect on thrombin-induced monocyte chemoattractant protein-1 release in S1P3-/- mice. In contrast to S1P receptors on lymphocytes, FTY720 did not desensitize vascular S1P receptors as arteries from FTY720-treated mice retained their vasodilator response to FTY720-phosphate.
Conclusions--We suggest that FTY720 inhibits atherosclerosis by suppressing the machinery involved in monocyte/macrophage emigration to atherosclerotic lesions. As vascular S1P receptors remained functional under FTY720 treatment, S1P agonists that selectively target the vasculature and not the immune system may be promising new drugs against atherosclerosis.
This article has been cited by other articles:
![]() |
G. Daum, A. Grabski, and M.A. Reidy Sphingosine 1-Phosphate: A Regulator of Arterial Lesions Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1439 - 1443. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kramer, E. Binder, T. Loof, Y. Wang-Rosenke, S. Martini, D. Khadzhynov, K. Budde, H.-H. Neumayer, and H. Peters The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy Am J Physiol Renal Physiol, July 1, 2009; 297(1): F218 - F227. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Skoura and T. Hla Lysophospholipid receptors in vertebrate development, physiology, and pathology J. Lipid Res., April 1, 2009; 50(Supplement): S293 - S298. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tolle, A. Pawlak, M. Schuchardt, A. Kawamura, U. J. Tietge, S. Lorkowski, P. Keul, G. Assmann, J. Chun, B. Levkau, et al. HDL-Associated Lysosphingolipids Inhibit NAD(P)H Oxidase-Dependent Monocyte Chemoattractant Protein-1 Production Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1542 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Wamhoff, K. R. Lynch, T. L. Macdonald, and G. K. Owens Sphingosine-1-Phosphate Receptor Subtypes Differentially Regulate Smooth Muscle Cell Phenotype Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1454 - 1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Hughes, S. Srinivasan, K. R. Lynch, R. L. Proia, P. Ferdek, and C. C. Hedrick Sphingosine-1-Phosphate Induces an Antiinflammatory Phenotype in Macrophages Circ. Res., April 25, 2008; 102(8): 950 - 958. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Klingenberg, J.-R. Nofer, M. Rudling, F. Bea, E. Blessing, M. Preusch, H. J. Grone, H. A. Katus, G. K. Hansson, and T. J. Dengler Sphingosine-1-Phosphate Analogue FTY720 Causes Lymphocyte Redistribution and Hypercholesterolemia in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2392 - 2399. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |